PharmSource-Catching the Next Wave: How Much Have CMOs Benefited from Biosimilars-2018 Edition

Mon Jan 14, 2019 - 11:30am UTC

The Exhaustive Study for “Global Biosimilars Market” Research Report is added on database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Dallas, United States – January 14, 2019

Biosimilars are drugs that are highly similar but not identical to branded “innovator” biologics: large molecule, immunogenic drugs produced from living cells. “Innovator” biologics are the first to be approved, and when their patent protection expires, biosimilars may be approved, in a similar way to small molecule branded drugs and their generics.

There are no clinically meaningful differences in quality, safety and efficacy between biosimilars and innovator biologics. The exact definition of a biosimilar varies by regulator.

Biosimilars bring competition to expensive innovator biologics and represent a cost-saving option for payers.

More than 50 biosimilars are approved in the EU, while the FDA lags behind with 17 approvals but is catching up fast. As more innovator biologics come off-patent in the near future, this will bring a huge opportunity for biosimilar companies and for biosimilar manufacturers.

Get Sample Copy of “Global Biosimilars Market” Report@

Key Questions Answered
– What biosimilars are marketed in the US and EU?
– How is biosimilar manufacturing and packaging outsourced?
– What therapies are in the biosimilar pipeline?
– In what regions is biosimilar development concentrated?
– How does biosimilar manufacturing differ by molecule type?
– When will innovator biologic patents expire, allowing biosimilar development?
– What proportion of biosimilar manufacturing is kept in-house?
– How will contract analytical testing services be affected by the rise of biosimilars?

Detailed view of –
– Marketed Innovator Biologics.
– Marketed Biosimilars.
– Innovator Biologic Patent Expiries and Waves of Biosimilar Opportunity.
– Biosimilar Clinical Pipeline.
– Existing CDMO Contracts for Biosimilars for API, Dose and Packaging.

Reasons to buy:
– This 74-page report gives important, expert insight you won’t find in any other source. 20 tables and figures throughout the report illustrate major points and trends. This report is required reading for –
– CMO executives who must have deep understanding of the biosimilar marketplace to make strategic planning and investment decisions.
– Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
– Pharmaceutical and Biotech companies involved in the development of innovator biologics or biosimilars.
– Investors that need a deeper understanding of the market to identify and value potential investment targets.

Make an Inquiry before Buying “Global Biosimilars Market” Report@

Key Players:
• AbbVie
• Accord Healthcare
• Advanced Accelerator Applications
• Aeterna Zentaris
• Aetos Biologics
• Alexion Pharmaceuticals
• Allpack
• AlphaMab
• Amgen
• APEIRON Biologics
• Apotex
• Aptevo Therapeutics
• AstraZeneca
• Baxter International
• Bayer
• Bayer Healthcare
• Beijing Fogangren Bio-Pharm Tech
• Biogen
• BioMarin Pharmaceutical
• BioReliance
• Boehringer Ingelheim BioXcellence
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Catalent
• Celgene
• Celltrion
• Chiesi Farmaceutici
• Chugai Pharmaceutical Co
• Clinuvel Pharmaceuticals
• Coherus BioSciences
• Cook Pharmica
• Dompe Farmaceutici
• Eli Lilly
• Elusys Therapeutics
• Emergent BioSolutions
• Endo International
• F. Hoffmann-La Roche
• Ferring International Center
• Finox Biotech
• GE Healthcare
• Gedeon Richter
• Gene Techno Science
• Genentech
• Genor BioPharma
• GlaxoSmithKline
• Grunenthal Group
• Horizon Pharma
• IDT Biologika
• Intas Pharmaceuticals
• Ipsen
• Ironwood Pharmaceuticals
• Jazz Pharmaceuticals
• Johnson & Johnson
• KBI Biopharma
• Kyowa Hakko Kirin
• La Jolla Pharmaceutical Company
• LG Chem
• MabPlex International
• MannKind Corp
• Medac
• Medice Arzneimittel Pütter & Co.
• MedImmune
• Merck & Co / MSD
• Merck KGaA
• Mustafa Nevzat Pharmaceuticals
• Mylan
• Novartis
• Novartis International
• Novelion Therapeutics
• Novo Nordisk AS
• Octapharma
• Ono Pharmaceutical Co
• Pall Corp
• Patheon
• PCI Pharma Services
• Pfizer
• Pharming Group
• Polymun Scientific Immunbiologische Forschung
• Portola Pharmaceuticals
• Protalix BioTherapeutics
• Regeneron Pharmaceuticals
• Rentschler Biopharma
• rEVO Biologics
• Richter Gedeon
• Richter-Helm Biologics & Co.
• Samsung Bioepis
• Samsung BioLogics
• Sandoz
• Sanofi
• ScinoPharm Taiwan
• Seattle Genetics
• Serenity Pharmaceuticals
• Servier
• Shanghai Mab Venture Biopharm
• ShangPharma Corporation
• Shenzen Techdow Pharmaceutical Co.
• Shire
• Sicor Biotech
• SK Chemicals
• Spectrum Pharmaceuticals
• Stada Arzneimittel
• Sun Pharma Advanced Research Company
• Swedish Orphan Biovitrum
• Synergy Pharmaceuticals
• Syngene International
• TaiMed Biologics
• Teva Pharmaceutical Industries
• The Medicines Company
• Theratechnologies
• ThromboGenics NV
• Ultragenyx Pharmaceutical
• United Therapeutics
• Vetter Pharma-Fertigung
• Walvax Biotechnology
• Wockhardt Contract Manufacturing
• WuXi AppTec
• Wuxi Biologics

Purchase this report online with 74 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Biosimilars Market”@

Key Points from TOC:
1. Executive Summary 4
2. Introduction 6
3. The Biosimilar Opportunity 7
4. Approved Biosimilars 10
5. Market Penetration 29
6. The Biosimilar Pipeline 36
7. Sourcing Arrangements for Biosimilars 42
8. Notes on Methodology 56
9. Appendix 57

Get More Information about “Global Biosimilars Market” Report@

About Us:
Orbis Research ( is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Info:
Name: Hector Costello
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A.
Phone: +1 (214) 884-6817

This news is published on Reuters.

VCNN is your primary source for all venture capital news. We provide the latest breaking news and insider stories straight from the venture capital scene. Contact us at: